22 search results for: patient burden

The Impact of Skin Fibrosis in <b>Patient</b>s with Prurigo Nodularis

videoanimation

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis

3 min

Dermatology

An animated infographic exploring the patient burden and pathophysiology of skin fibrosis in prurigo nodularis, specifically detailing how fibrotic pathways are driven and the key molecules involved.

ADVENT On Air | Defining AD in Pediatric <b>Patient</b>s

Podcast

ADVENT On Air | Defining AD in Pediatric Patients

15 min

Dermatology

Learn more about the journey of pediatric patients with AD in this conversation between Drs. Lisa Swanson and Weily Soong.

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for <b>Patient</b> Management

Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

5 min

Dermatology

An infographic summarizing the clinical manifestations and pathophysiological processes of PN.

Chronic Spontaneous Urticaria (CSU) Interactive <b>Patient</b> Case

interactivity

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case

10 min

Dermatology

Learn more about the guideline-based diagnosis of chronic spontaneous urticaria with this interactive patient case.

Comorbidities and Disease <b>Burden</b> in CSU

expert video

Comorbidities and Disease Burden in CSU

10 min

Dermatology

In their interview Drs. Maurer and Ensina shed light on the significant burden of comorbidities in CSU.

High <b>Burden</b> of Atopic Dermatitis in Children

expert video

High Burden of Atopic Dermatitis in Children

1 min

Dermatology

Explore the debilitating effects that impact day-to-day functioning in pediatric patients with atopic dermatitis – a short soundbite from EADV 2022.

expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

1 min

Dermatology

Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.

expert video

Differences in Itch in AD, PN, and CSU

2 min

Dermatology

Dr. Shawn Kwatra reviews the distinct characteristics of itch, and the associated patient burden in AD, PN, and CSU.

interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

10 min

Dermatology

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.

The <b>Burden</b> of Atopic Dermatitis in Children – Skin Infections and More Severe Disease

expert video

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease

1 min

Dermatology

Dr. Mark Koh talks about skin infections and their impact on disease severity.

expert video

Targeted Therapies for Children With Atopic Dermatitis - Expert Interview

9 min

Dermatology

Dermatologist Elaine Seigfried discusses burden & therapeutic landscape of pediatric atopic dermatitis

expert video

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

20 min

Dermatology

This video features Dr. Eric Simpson's presentation on the importance of achieving disease control in adults with moderate-to-severe AD. Dr. Simpson discusses how adult patients and HCPs talk about disease control and the tools available to help define it. He also explores the roles of IL-4 and IL-13 in the pathophysiology of AD, including how both cytokines promote inflammation and, in turn, contribute to the cumulative burden of the disease. The video concludes with a brief panel discussion.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwitzerlandChange country/region